Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2016

01-04-2016 | Article

Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes

Authors: Rakel F. Johansen, Esben Søndergaard, Lars Peter Sørensen, Anne Grethe Jurik, Jens S. Christiansen, Søren Nielsen

Published in: Diabetologia | Issue 4/2016

Login to get access

Abstract

Aims/hypothesis

Hypertriacylglycerolaemia is a hallmark of diabetic dyslipidaemia with increased concentrations of triacylglycerol (TG)-rich VLDL1 particles. However, whether VLDL1 secretion or removal is abnormal in type 2 diabetes remains unclear. The aim of this study was to compare basal and insulin-mediated VLDL1- and VLDL2-TG kinetics in men with type 2 diabetes and healthy men using a novel direct VLDL1- and VLDL2-TG labelling method.

Methods

Twelve men with type 2 diabetes and 12 healthy men matched for age and BMI were recruited. VLDL1- and VLDL2-TG turnover were measured during a 4 h basal period and a 3.5 h hyperinsulinaemic clamp period using a primed-constant infusion of ex vivo labelled VLDL1-TG and VLDL2-TG.

Results

Basal VLDL1-TG and VLDL2-TG secretion rates were similar in men with diabetes and healthy men. During hyperinsulinaemia, VLDL1-TG secretion rates were suppressed significantly in both groups, whereas no suppression of VLDL2-TG secretion rate was observed. VLDL1-TG to VLDL2-TG transfer rate was not significantly different from zero in both groups, while VLDL1-TG fatty acid oxidation rate was substantial, with a contribution to total energy expenditure of approximately 15% during postabsorptive conditions. VLDL1 and VLDL2 particle size (TG/apolipoprotein B [apoB] ratio) and apoB-100 concentration were unaltered by hyperinsulinaemia in men with type 2 diabetes, but significantly reduced in healthy men.

Conclusions/interpretation

Insulin inhibits VLDL1-TG secretion rate similarly in age- and BMI-matched men with type 2 diabetes and healthy men, while VLDL2-TG secretion is unaltered by hyperinsulinaemia. However, VLDL1- and VLDL2-apoB levels are not lowered by hyperinsulinaemia in men with type 2 diabetes, which is indicative of a diminished hepatic response to insulin.

Trial registration

ClinicalTrials.gov NCT01564550
Literature
1.
Carr MC, Brunzell JD (2004) Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89:2601–2607CrossRefPubMed
2.
Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ (2000) Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189–197CrossRefPubMed
3.
Adiels M, Olofsson SO, Taskinen MR, Boren J (2006) Diabetic dyslipidaemia. Curr Opin Lipidol 17:238–246CrossRefPubMed
4.
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749CrossRefPubMed
5.
Packard CJ, Shepherd J (1997) Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542–3556CrossRefPubMed
6.
Duvillard L, Florentin E, Pont F et al (2011) Endogenous chronic hyperinsulinemia does not increase the production rate of VLDL apolipoprotein B: proof from a kinetic study in patients with insulinoma. J Clin Endocrinol Metab 96:2163–2170CrossRefPubMed
7.
Durrington PN, Newton RS, Weinstein DB, Steinberg D (1982) Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest 70:63–73CrossRefPubMedPubMedCentral
8.
Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G (1995) Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158–166CrossRefPubMedPubMedCentral
9.
10.
Lewis GF, Uffelman KD, Szeto LW, Steiner G (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833–842CrossRefPubMed
11.
Vatner DF, Majumdar SK, Kumashiro N et al (2015) Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci U S A 112:1143–1148CrossRefPubMedPubMedCentral
12.
Adiels M, Boren J, Caslake MJ et al (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25:1697–1703CrossRefPubMed
13.
Taskinen MR, Packard CJ, Shepherd J (1990) Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017–1027CrossRefPubMed
14.
Gill JM, Brown JC, Bedford D et al (2004) Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 176:49–56CrossRefPubMed
15.
Adiels M, Packard C, Caslake MJ et al (2005) A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res 46:58–67CrossRefPubMed
16.
Gormsen LC, Jensen MD, Nielsen S (2006) Measuring VLDL-triglyceride turnover in humans using ex vivo-prepared VLDL tracer. J Lipid Res 47:99–106CrossRefPubMed
17.
Sorensen LP, Gormsen LC, Nielsen S (2009) VLDL-TG kinetics: a dual isotope study for quantifying VLDL-TG pool size, production rates, and fractional oxidation in humans. Am J Physiol Endocrinol Metab 297:E1324–E1330CrossRefPubMed
18.
Redgrave TG, Carlson LA (1979) Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res 20:217–229PubMed
19.
Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A (1993) Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 91:748–758CrossRefPubMedPubMedCentral
20.
Lindgren FT, Jensen LC, Hatch FT (1972) Blood lipids and lipoproteins. Wiley, New York, pp 221–248
21.
Mills GL, Lane PA, Weech PK (1984) A guidebook to lipoprotein technique. Amsterdam, pp 18-116
22.
Tong H, Knapp HR, VanRollins M (1998) A low temperature flotation method to rapidly isolate lipoproteins from plasma. J Lipid Res 39:1696–1704PubMed
23.
Heiling VJ, Miles JM, Jensen MD (1991) How valid are isotopic measurements of fatty acid oxidation? Am J Physiol 261:E572–E577PubMed
24.
Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628–634PubMed
25.
Sorensen LP, Sondergaard E, Nellemann B, Christiansen JS, Gormsen LC, Nielsen S (2011) Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men. Diabetes 60:2257–2264CrossRefPubMedPubMedCentral
26.
Sidossis LS, Coggan AR, Gastaldelli A, Wolfe RR (1995) A new correction factor for use in tracer estimations of plasma fatty acid oxidation. Am J Physiol 269:E649–E656PubMed
27.
Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755–765CrossRefPubMed
28.
Adiels M, Westerbacka J, Soro-Paavonen A et al (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50:2356–2365CrossRefPubMed
29.
Malmstrom R, Packard CJ, Caslake M et al (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454–462CrossRefPubMed
30.
Melish J, Le NA, Ginsberg H, Steinberg D, Brown WV (1980) Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am J Physiol 239:E354–E362PubMed
31.
Malmstrom R, Packard CJ, Caslake M et al (1998) Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 47:779–787CrossRefPubMed
32.
Taskinen MR, Adiels M, Westerbacka J et al (2011) Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 31:2144–2150CrossRefPubMed
33.
Beltz WF, Kesaniemi YA, Howard BV, Grundy SM (1985) Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. J Clin Invest 76:575–585CrossRefPubMedPubMedCentral
34.
Gaw A, Packard CJ, Lindsay GM et al (1995) Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 36:158–171PubMed
35.
Malmstrom R, Packard CJ, Watson TD et al (1997) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454–1464CrossRefPubMed
36.
Sondergaard E, Sorensen LP, Rahbek I, Gormsen LC, Christiansen JS, Nielsen S (2012) Postprandial VLDL-triacylglycerol secretion is not suppressed in obese type 2 diabetic men. Diabetologia 55:2733–2740CrossRefPubMed
37.
Jensen MD, Nielsen S (2007) Insulin dose response analysis of free fatty acid kinetics. Metabolism 56:68–76CrossRefPubMed
Metadata
Title
Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes
Authors
Rakel F. Johansen
Esben Søndergaard
Lars Peter Sørensen
Anne Grethe Jurik
Jens S. Christiansen
Søren Nielsen
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3856-5

Other articles of this Issue 4/2016

Diabetologia 4/2016 Go to the issue

Commentary

Sitting and chronic disease: where do we go from here?

Article

Metabolomics uncovers the role of adipose tissue PDXK in adipogenesis and systemic insulin sensitivity

Letter

The pancreas in humans with and without diabetes

Letter

Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]

Article

Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation

Article

Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits